|
Patent landscape, scope, and claims: |
Scope and claims of US Patent 9,827,317 (liposomal aminoglycoside, neutral phospholipid/sterol, defined lipid:drug ratio, and 0.1–1.0 µm size) and what the patent blocks in the US
US 9,827,317 claims a tightly defined liposomal aminoglycoside platform: a liposome with (i) a lipid bilayer made of a neutral phospholipid plus a sterol, (ii) aminoglycoside encapsulated inside (including specific salts), (iii) a maximum lipid:aminoglycoside weight ratio of 0.75:1, and (iv) a mean liposome diameter of about 0.1 µm to about 1.0 µm. Dependent claims narrow to specific aminoglycosides (amikacin, tobramycin, streptomycin, etc.), phospholipid species (DPPC), sterol (cholesterol), specific salts (sulfates), narrower size ranges, and add downstream embodiments: nebulized spray compositions and therapeutic methods for pulmonary infections including Pseudomonas and mycobacterial disease, with additional specificity for cystic fibrosis and for chronic Pseudomonas aeruginosa.
Core independent claim scope
- Claim 1 defines the product-by-structure/parameters:
- Liposome with lipid bilayer consisting of:
- neutral phospholipid + sterol
- Aminoglycoside (or pharmaceutically acceptable salt) encapsulated in liposome
- Lipid:aminoglycoside weight ratio in the formulation ≤ 0.75:1
- Mean diameter about 0.1 µm to about 1.0 µm
- Claims 17–23 add delivery format (nebulized spray) tied to the claimed liposomal formulations.
- Claims 24–56 add use claims directed to treating pulmonary infections by administering the claimed liposomal formulation, with broad pathogen lists and then narrower enumerated pathogens and patient populations.
- Claims 59–60 add specific nebulized spray embodiments corresponding to specific aminoglycoside/salt/phospholipid/sterol dependent claim groupings.
What does US 9,827,317 claim in plain terms? (liposomal aminoglycoside structure, ratios, size, and bilayer composition)
Claim 1 limitations (the infringement gatekeepers)
- Encapsulated aminoglycoside in a liposome
- Aminoglycoside or a pharmaceutically acceptable salt “encapsulated therein.”
- Bilayer composition
- The lipid bilayer comprises:
- a neutral phospholipid
- a sterol
- “Neutral phospholipid” is broad, but dependent claims specify phosphatidylcholine and DPPC.
- Sterol is broad, but dependent claims specify cholesterol.
- Maximum lipid:aminoglycoside weight ratio
- “weight ratio of lipid to the aminoglycoside… is 0.75:1 or less.”
- This parameter is likely the most defensible distinguishing feature against generic liposomal approaches that dilute drug loading to reduce leakage/toxicity.
- Mean diameter window
- “mean diameter of about 0.1 μm to about 1.0 μm.”
- Dependent claims carve out narrower ranges:
- about 0.2–1.0 µm (claim 15)
- about 0.2–0.5 µm (claim 16)
Practical reading for enforceability
- A competitor does not need to match every dependent feature to infringe if Claim 1 is met. But Claim 1 requires the combination of:
- (neutral phospholipid + sterol) bilayer,
- drug encapsulation,
- lipid:drug weight ratio ≤ 0.75:1,
- mean size 0.1–1.0 µm.
Dependent claim coverage map (how claim scope expands/narrows)
- Aminoglycoside scope
- Claim 2 lists multiple aminoglycosides.
- Claims 3–5 carve out specific ones: amikacin, streptomycin, tobramycin.
- Phospholipid scope
- Claim 6 says neutral phospholipid is phosphatidylcholine.
- Claim 7 narrows to DPPC.
- Sterol scope
- Claim 8 narrows to cholesterol.
- Claim 9 fixes DPPC + cholesterol.
- Claim 10 fixes amikacin + DPPC + cholesterol.
- Salt scope
- Claims 11–14 are salt-specific: aminoglycoside sulfate; then sulfate subtypes for amikacin/tobramycin/streptomycin.
- Size narrowing
- Claims 15–16 define mean diameter windows.
- Delivery format
- Claims 17–23 are nebulized sprays tied to Claim 1 and specific dependent formulation claims.
- Therapeutic uses
- Claims 24–47 cover pulmonary infection treatment with enumerated pathogens and patient subsets.
- Claims 48–56 and 49–57/58 add nested aminoglycoside/salt/phospholipid/sterol/size specificity in method claims.
Which aminoglycosides and salt forms are covered by the patent claims? (amikacin vs tobramycin vs streptomycin and sulfate-only subsets)
Breadth at Claim 1 level
- Claim 1 covers “an aminoglycoside or a pharmaceutically acceptable salt thereof.” That is a broad genus.
Dependent coverage explicitly enumerated
- Claim 2: amikacin, gentamicin, tobramycin, streptomycin, netilmicin, kanamycin (and salts).
- Claim 3: amikacin (or salt).
- Claim 4: streptomycin (or salt).
- Claim 5: tobramycin (or salt).
Sulfate-specific claim set
- Claim 11: “aminoglycoside is an aminoglycoside sulfate.”
- Claims 12–14:
- Claim 12: amikacin sulfate
- Claim 13: tobramycin sulfate
- Claim 14: streptomycin sulfate
Method claims tie
- Nearly all method-specific dependent claims later fix amikacin sulfate as the aminoglycoside (claims 37–48).
- Additional method dependencies for phospholipid/sterol focus on DPPC + cholesterol (claims 49–58).
Infringement implications
- A product with encapsulated aminoglycosides that are not in the enumerated list could still infringe Claim 1 if it is “an aminoglycoside” and meets bilayer/ratio/size constraints.
- A product using non-sulfate salts is captured by Claim 1 and generic “salt” language, but only sulfate-specific variants land in the dependent claims.
What lipid bilayer composition requirements are imposed? (neutral phospholipid + sterol, with DPPC and cholesterol as anchors)
Claim 1 bilayer requirement
- Lipid bilayer comprises:
- a neutral phospholipid
- a sterol
This excludes (for Claim 1) bilayers that rely on:
- charged phospholipids without a neutral phospholipid component,
- or bilayer compositions without sterol.
Dependent claim anchors
- Claim 6: neutral phospholipid is phosphatidylcholine.
- Claim 7: DPPC (a specific phosphatidylcholine).
- Claim 8: sterol is cholesterol.
- Claim 9: DPPC + cholesterol.
- Claim 10: amikacin + DPPC + cholesterol.
Key design-around lever
- If a formulation omits sterol or uses sterols replaced by non-sterol components, it risks falling outside Claim 1.
- If lipid:aminoglycoside loading is altered above the 0.75:1 threshold, even with neutral phospholipid + sterol, it avoids the explicit ratio limitation.
How does the lipid:aminoglycoside weight ratio limit (≤0.75:1) shape the patent’s novelty and infringement risk?
Claim 1 numeric limit
- “weight ratio of lipid to the aminoglycoside… is 0.75:1 or less.”
That is a hard quantitative constraint. For infringement, the accused formulation must satisfy the ratio as defined in the claim.
Dependent reliance
- None of the dependent claims relax the ratio; they layer on additional specificity (drug identity, salt form, DPPC/cholesterol, size ranges, and delivery/use).
Implication for commercial competitors
- Many liposome programs use conservative loading ratios to improve stability or reduce toxicity. If competitors target higher lipid-to-drug ratios, they may reduce the risk of matching Claim 1.
- If competitors engineer higher loading such that ratio drops below 0.75:1, they face direct Claim 1 product infringement exposure.
What are the size constraints (0.1–1.0 µm mean diameter) and how do narrower windows expand coverage?
Claim 1 size range
- Mean diameter about 0.1 µm to about 1.0 µm.
Dependent size claims
- Claim 15: about 0.2–1.0 µm
- Claim 16: about 0.2–0.5 µm
- Claim 28–29: method claims incorporate size limitations (claim 28 repeats 0.2–1.0; claim 29 repeats 0.2–0.5).
Implication
- Competitors with sub-100 nm formulations (below ~0.1 µm mean) risk stepping outside Claim 1.
- Competitors with larger particles (above ~1.0 µm mean) also risk non-infringement.
Are nebulized sprays covered? (what claim language ties delivery format to the liposomal formulation)
Nebulized spray claims
- Claim 17: nebulized spray comprising the formulation of Claim 1.
- Claims 18–23: nebulized sprays comprising formulations corresponding to dependent claims 3, 6, 7, 8, 9, 10 (amikacin/DPPC/cholesterol specific sets).
Downstream exposure
- Even if a formulation meets Claim 1, a non-nebulized delivery method could avoid claims 17–23, but the formulation itself (Claim 1) still presents risk for product-focused enforcement.
- If the formulation is used in a nebulized spray, the delivery-specific claims add breadth.
What pulmonary infection indications are claimed? (pathogen list and patient subsets)
Method of treatment independent claim
- Claim 24: method of treating a patient for a pulmonary infection by administering a therapeutically effective amount of Claim 1 formulation.
Pathogen enumeration in dependent claim 25
- Pulmonary infection pathogens listed:
- Pseudomonas, staphylococcal, streptococcal, Escherichia, Klebsiella, Enterobacter, Serratia, Haemophilus, Yersinia, Burkholderia, or mycobacterial infection.
Mycobacterial specificity (claims 26, 32)
- Claim 26: mycobacterial infection.
- Claim 32: specific mycobacterial species:
- M. tuberculosis
- M. avium complex (MAC, includes M. avium and M. intracellulare)
- M. kansasii
- M. xenopi
- M. marinum
- M. ulcerans
- M. fortuitum complex (M. fortuitum and M. chelonae)
Pseudomonas specificity (claims 27, 33, 34, 36)
- Claim 27: Pseudomonas infection.
- Claim 33: P. aeruginosa.
- Claim 34: chronic Pseudomonas infection.
- Claim 36: chronic P. aeruginosa.
Cystic fibrosis (claim 30)
- Claim 30: patient is a cystic fibrosis patient.
Size dependence in methods
- Claims 28 and 29: method incorporates mean diameter ranges 0.2–1.0 µm and 0.2–0.5 µm.
Aminoglycoside specificity in methods
- Claims 31 and 37–48 repeatedly fix amikacin (claim 31) and amikacin sulfate (claims 37–48).
DPPC + cholesterol dependence in methods
- Claims 49–58 repeatedly require DPPC + cholesterol in conjunction with the size-dependent/nested method sets.
How do the dependent method claims stack? (what combinations are expressly required in practice)
The method claims use a hierarchical structure: Claim 24 is the base; dependent claims then add pathogen specificity and further add formulation parameter constraints.
Common stack patterns
- Pulmonary infection → Pseudomonas → chronic P. aeruginosa → amikacin sulfate → (DPPC + cholesterol in some nested claims).
- Pulmonary infection → mycobacterial species list → amikacin sulfate → (DPPC + cholesterol in nested claims).
- Pulmonary infection → cystic fibrosis → amikacin sulfate → (DPPC + cholesterol in nested claims).
- Pulmonary infection → mean diameter subset (0.2–1.0 or 0.2–0.5) → amikacin sulfate → (DPPC + cholesterol in nested claims).
What this means for challengers
- A generic entrant or biosimilar-equivalent would not only need to match the formulation but also the intended use path, since method claims are tied to diagnosis and treatment steps.
What does the patent likely cover commercially? (where US 9,827,317 is most enforceable)
Highest enforceability points
- Any nebulized liposomal aminoglycoside formulation that meets Claim 1 product constraints (bilayer neutral phospholipid + sterol, lipid:drug ≤0.75:1, mean size 0.1–1.0 µm, encapsulated aminoglycoside).
- Any label-aligned clinical use of that formulation for pulmonary infection indications covered by the claim pathogen lists (especially P. aeruginosa and mycobacterial diseases).
- Specialized populations (cystic fibrosis and chronic infection contexts) covered by dependent method claims.
Where infringement risk drops
- Formulations outside particle-size range (mean <0.1 µm or >1.0 µm).
- Formulations using bilayers not satisfying “neutral phospholipid + sterol.”
- Formulations with lipid:aminoglycoside weight ratio above 0.75:1.
Which claims look most important for a validity or design-around strategy? (numeric ratio and bilayer composition)
Top quantitative/structural bottlenecks
- Lipid:aminoglycoside weight ratio (≤0.75:1).
- Mean liposome diameter (0.1–1.0 µm).
- Bilayer composition rule: neutral phospholipid + sterol.
Secondary levers
- Delivery form: nebulized spray
- Specific species: DPPC and cholesterol, and sulfate forms (amikacin sulfate)
A challenger usually attacks one or more of the three bottlenecks. A licensor usually treats them as the “core infringement moat.”
What is the patent landscape around US 9,827,317? (priority map and adjacent claim themes)
Only the claim text is provided; no bibliographic data (inventors, assignee, priority/filing dates, other US-family numbers) is included. A complete landscape cannot be produced from claims alone without risking inaccuracies.
What can be concluded from claim themes:
- The invention is positioned at the intersection of:
- liposomal encapsulation of aminoglycosides,
- specifically controlled loading ratios (lipid:drug),
- size-controlled nanoparticles suitable for pulmonary delivery,
- nebulization-compatible dosage forms,
- and treatment of chronic lung infections (notably P. aeruginosa) and mycobacteria.
Landscape categories that commonly surround such patents
- Prior art in liposomal aminoglycosides (including other encapsulation and neutral lipid systems).
- Prior art in particle sizing and nebulizable aerosol performance.
- Prior art in mycobacterial and Pseudomonas pulmonary inhalation regimens with aminoglycosides.
- Formulation patents using different lipid chemistries (charged lipids, sterol-free bilayers) or different loading ratios.
No further, claim-accurate enumeration of specific US patents or litigation events can be provided without bibliographic records.
Key Takeaways
- US 9,827,317 is anchored by a tightly defined liposome formulation: neutral phospholipid + sterol bilayer, encapsulated aminoglycoside, lipid:drug weight ratio ≤0.75:1, and mean diameter about 0.1–1.0 µm.
- Dependent claims narrow to particular drugs (including amikacin, tobramycin, streptomycin), DPPC/cholesterol, and sulfate salts (especially amikacin sulfate), and narrow particle size ranges to 0.2–1.0 µm and 0.2–0.5 µm.
- The patent extends beyond the formulation into nebulized spray compositions and into methods of treating pulmonary infections with broad pathogen coverage plus specific dependent claims for P. aeruginosa (including chronic) and mycobacterial species, with cystic fibrosis as an additional population anchor.
- Quantitative limits (0.75:1 lipid:aminoglycoside and 0.1–1.0 µm mean size) and the bilayer composition rule (neutral phospholipid + sterol) are the central enforceability and design-around pressure points.
FAQs
-
Does US 9,827,317 require DPPC and cholesterol to infringe Claim 1?
No. DPPC and cholesterol are in dependent claims (e.g., claims 7–10) while Claim 1 only requires a neutral phospholipid and a sterol.
-
Can a nebulized aminoglycoside liposome avoid infringement by using a different aminoglycoside salt form?
Claim 1 covers “a pharmaceutically acceptable salt thereof,” so changing to a non-sulfate salt may still fall within Claim 1 if other constraints are met.
-
What change most directly avoids Claim 1: lowering particle size below 0.1 µm or changing lipid loading ratio?
Both can avoid Claim 1 if they move the formulation outside the claimed mean diameter range or raise lipid:aminoglycoside weight ratio above 0.75:1.
-
Are chronic Pseudomonas and mycobacterial infections required for infringement of product claims?
No. Those are method-of-treatment dependent claim contexts. Product claim infringement depends on matching Claim 1 formulation parameters.
-
If a formulation meets Claim 1 but is administered by a non-nebulized route, which claims remain relevant?
Nebulized spray claims (17–23) may not apply, but Claim 1 product infringement exposure remains if the formulation is made/sold/used within the scope of Claim 1.
References
- United States Patent No. 9,827,317. (Claim text as provided by user.)
More… ↓
⤷ Start Trial
|
